IQVIA Holdings (IQV) has drawn fresh attention after unveiling IQVIA.ai at NVIDIA GTC, a new agentic AI platform built with NVIDIA tools to support life sciences workflows across clinical, commercial and real world settings.
See our latest analysis for IQVIA Holdings.
At a share price of US$166.47, IQVIA has seen a 2.17% 7 day share price return and a 1.23% 30 day share price return. Its 1 year total shareholder return of 9.65% and 5 year total shareholder return of 10.76% indicate comparatively weaker momentum over longer periods as investors weigh the IQVIA.ai launch against mixed longer term performance.
If IQVIA.ai has caught your attention, it may be worth scanning other healthcare focused AI names using our curated list of 35 healthcare AI stocks.
IQVIA’s share price has fallen year to date despite the IQVIA.ai launch, while the stock still trades below analyst targets and an estimated intrinsic value. Is this an undervalued AI-in-healthcare opportunity, or is the market already pricing in potential future growth?
Most Popular Narrative: 33.4% Undervalued
At a last close of $166.47, the most followed narrative places IQVIA’s fair value at $250, implying a sizeable gap between current pricing and the long term view.
Continued investment in and deployment of proprietary platforms and agentic AI solutions, coupled with strategic collaborations and industry recognitions, increase switching costs and provide competitive barriers, positioning IQVIA to capture greater market share and support long term revenue growth and margin improvement.
Curious what has to happen for that valuation to make sense? Revenue, margins, earnings per share, even the future P/E are all carefully wired into this narrative. The full set of assumptions is where the story really gets interesting.
Result: Fair Value of $250 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, pressure on CRO pricing and IQVIA's higher leverage could still limit margin improvement and leave the business more exposed if demand weakens.
Find out about the key risks to this IQVIA Holdings narrative.
Next Steps
Mixed views on IQVIA are clear, with both risks and rewards in focus. It makes sense to check the numbers yourself and decide whether the current pricing stacks up against the company’s underlying story by reviewing the 4 key rewards and 1 important warning sign
Looking for more investment ideas?
If IQVIA has sparked your interest, do not stop here. Broaden your watchlist with other focused ideas that could suit different goals and risk levels.
- Target potential mispricings by scanning companies that look overlooked on quality and valuation using the 49 high quality undervalued stocks.
- Strengthen your search for stability by reviewing companies filtered through the solid balance sheet and fundamentals stocks screener (40 results).
- Hunt for under the radar opportunities by checking the screener containing 25 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com